Lunai Bioworks Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RENB research report →
Companyrenovarogroup.com
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21.
- CEO
- David H. Weinstein
- IPO
- 2018
- Employees
- 25
- HQ
- Los Angeles, CA, US
Price Chart
Valuation
- Market Cap
- $32.92M
- P/E
- -0.04
- P/S
- 190.97
- P/B
- -0.59
- EV/EBITDA
- -0.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -360.71%
- Op Margin
- -46991.97%
- Net Margin
- -612568.11%
- ROE
- 892.52%
- ROIC
- 120.87%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-178,007,489 · -120.72%
- EPS
- $-1.08 · 87.14%
- Op Income
- $-188,966,000
- FCF YoY
- 28.68%
Performance & Tape
- 52W High
- $21.00
- 52W Low
- $1.12
- 50D MA
- $1.96
- 200D MA
- $4.41
- Beta
- 0.53
- Avg Volume
- 218.51K
Get TickerSpark's AI analysis on RENB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 25 | William Anderson Wittekind | other | 350,000 |
| Jan 21, 25 | van Tilburg Maurice | other | 1,000,000 |
| Jan 21, 25 | van Tilburg Maurice | other | 250,000 |
| Jan 21, 25 | Fuentes Nathen | other | 250,000 |
| Jan 6, 25 | Fuentes Nathen | other | 0 |
| Nov 4, 24 | Collins Mark Anthony | other | 120,968 |
| Nov 4, 24 | Calder Douglas W | other | 120,968 |
| Nov 4, 24 | Tarsh Simon | other | 58,500 |
| Nov 4, 24 | MCNULTY JAMES A | other | 120,968 |
| Oct 14, 24 | van Tilburg Maurice | other | 0 |
Our RENB Coverage
We haven't published any research on RENB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RENB Report →